A marker for early diagnosis and early warning of metastasis of lung cancer and kit for its preparation

Abstract

The invention relates to a marker for early lung cancer diagnosis and prediction of distant metastasis based on platelet LncRNA-STON2 and a kit for its preparation, belonging to the field of medical and health care. The marker is selected from plasma platelet LncRNA-STON2; the kit for preparing the marker includes: a reverse transcription reaction system, a fluorescent quantitative PCR reaction system and an internal reference system; meanwhile, a preparation method of the kit is also provided. The invention proposes for the first time that the expression level of LncRNA‑STON2 in plasma platelets of patients with lung cancer is significantly higher than that of healthy donors. ROC curve analysis shows that the AUC is 0.613, the sensitivity is 61.5%, and the specificity is 59.9%. Compared with healthy donors, the expression of LncRNA-STON2 was significantly increased in early-stage lung cancer patients. ROC curve analysis showed that the AUC was 0.713, the sensitivity was 69.2, and the specificity was 71.9%.

Description

technical field [0001] The invention relates to a platelet LncRNA-STON2-based marker for early lung cancer diagnosis and prediction of distant metastasis and a kit for its preparation, belonging to the field of medical and health care. Background technique [0002] Lung cancer is a malignant tumor with the highest mortality and morbidity in all countries in the world and also in my country. Its onset is hidden, and its early clinical manifestations lack specificity. Most patients are already in locally advanced stage or distant metastasis when they are diagnosed, and the prognosis is often poor. 5 The annual survival rate is only 2%. Therefore, there is an urgent need for a more sensitive diagnostic marker to provide an objective basis for early diagnosis, early treatment and prognosis of lung cancer with distant metastasis. [0003] Platelets are anuclear blood cells with a diameter of 2-4 μm, derived from megakaryocytes in the bone marrow, with a short half-life of only 7-...

AI Technical Summary

Problems solved by technology

[0004] Existing clinical diagnostic techniques such as X-ray and B-ultrasound cannot be detected in the early clinical stage, while CT, MRI and PET examinations can find smaller tumor tissues, but their specificity is low, and pathological biopsy is still needed to diagnose

The use of endoscopes such as fiberoptic bronchoscopes can improve the diagnosis rate of non-small cell lung cancer, but they are all interventional examinations, which cause great damage and pain to patients, and require high technical skills for operators, and not all parts of the lungs Biopsy can be taken, not suitable for large-scale population screening and census

Images